Osteopontin is elevated in Parkinson’s disease and its absence leads to reduced neurodegeneration in the MPTP model
Walter Maetzler(Centre Hospitalier Universitaire de Lille), Cordula Nitsch(University of Basel), Jakob C. Mueller(Max Planck Institute for Ornithology), Arthur Melms(Hertie Institute for Clinical Brain Research), Natalie Schalamberidze(Hertie Institute for Clinical Brain Research), Thomas Gasser(Hertie Institute for Clinical Brain Research), Lucy Liaw(MaineHealth), Klaus Schott(University of Tübingen), Daniela Berg(Christian-Albrechts-Universität zu Kiel)
Cited by 127
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
MDS research criteria for prodromal Parkinson's disease
|Movement Disorders|2015|1.3k